While anecdotal, there were real patients, I don’t recall if it was in the basket or TNBC trial, who also had glioblastoma which responded to Leronlimab. To use Jay’s words, that is a VERY provocative signal. I get your point about a mouse study, but if we publish patient data we already have and couple it with clear data on a mouse model, it should turn heads and should lead at least to a phase 2 study.